Topic:

Cancer Vaccines

Latest Headlines

Latest Headlines

Vax, hormone combo could up efficacy in prostate cancer

Prostate cancer could affect as many as one in 6 men during their lifetime, according to the U.S. National Cancer Institute, and for some their cancers recur and become hormone-resistant. The Cancer Institute of New Jersey and the National Cancer Institute have hooked up to see if combining a vaccine and hormone treatment will improve the response.

Polynoma's melanoma vax pushes into late-stage clinical trials

Polynoma has started a Phase III trial of its therapeutic melanoma vaccine, POL-103A, following approval from the FDA in January 2012. The trial, known as the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS), will involve 1,059 patients in 14 countries across the U.S. and Europe who have Stage IIb, IIc or III melanoma and who have had surgery.

Tumor necrosis factor supports cancer vaccine

Researchers from the University of Western Australia found that low doses of TNFα (tumor necrosis factor α) targeted to a pancreatic tumor enhanced the ability of immune cells (T cells) to get inside the tumor.

Vitamin D boosts TB shot as cancer therapy

The Bacillus Calmette-Guérin vaccine works in superficial bladder cancer, treating early stage disease and cutting recurrences. Vitamin D is linked with boosting the immune system, so researchers are looking at mice with bladder cancer to see what happens when you combine the two.

Vax-chemo combo offers some hope in pancreatic cancer

Pancreatic cancer is hard to treat, but adding a cancer vaccine to standard chemotherapy could boost survival.

Carbohydrate, vaccine combination could push melanoma immunotherapy forward

Galectin Therapeutics has started treating patients with advanced disease in a Phase I/II trial to see if combining its galectin inhibitor GM-CT-01 with a peptide-based cancer vaccine developed at the Ludwig institute improves the outcome of patients with advanced metastatic melanoma.

Biovest makes a move on the EU market with BiovaxID

Biovest International's stock has risen by 15% on two pieces of news about its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, BiovaxID.

Existing drugs boost new cancer vax responses

Cancer vaccines are becoming an increasingly attractive focus of study, but there are still perils and pitfalls along the way to success. Two recent studies have looked at ways to get around these, focusing on experimental cancer vaccines boosted by existing drugs.

'Designer' lymph nodes could boost cancer vaccines

Researchers at the Moffitt Cancer Center are developing "designer" lymph nodes that could be used to boost the effects of cancer vaccines.

New DCVax-L brain cancer vaccine trial starts enrolling

Another site in the U.S. has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme.